# The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter

> **NCT07666984** · PHASE4 · COMPLETED · sponsor: **Cukurova University** · enrollment: 86 (actual)

## Conditions studied

- Neuromuscular Blockade Reversal Agent

## Interventions

- **DRUG:** Sugammadex 2 mg/kg
- **DRUG:** Neostigmine + Atropine

## Key facts

- **NCT ID:** NCT07666984
- **Lead sponsor:** Cukurova University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2026-06-04
- **Primary completion:** 2026-09-23
- **Final completion:** 2026-09-23
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2026-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07666984

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07666984, "The Effect of Neostigmine and Sugammadex on the Optic Nerve Sheath Diameter". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07666984. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*